Merck (MRK) said Tuesday it has entered an exclusive licensing agreement with Jiangsu Hengrui Pharmaceuticals for HRS-5346, an oral lipoprotein(a) inhibitor in phase 2 trials in China for cardiovascular disease.
Under the deal, Merck will have global rights to develop, manufacture, and commercialize HRS-5346, excluding the Greater China region, with Hengrui receiving a $200 million upfront payment, potential milestone payments up to $1.77 billion, and royalties on sales, the companies said.
The transaction, subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act and other conditions, is expected to close in Q2, Merck added.
Merck expects to record a pre-tax charge of $200 million, or $0.06 per share, in the quarter the deal closes, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。